


5 We Claim:

1. A compound having the Formula I



wherein

10 R^1 is $-CO_2CH_3$ or $-H$;
 R^2 is $-CH_2CH_3$, $-CH_2CH_2OH$, $-CH_2CO_2H$, $-CH_2CO_2A$, and $-CH_2CH_2OA$, wherein A is 3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid; and
 R^3 is $-H$, $-CO_2CH_2CH_3$, $-CO_2CH_2CH_2OH$, $-CO_2CH_2CO_2H$,

15 $-CO_2CH_2CH_2OA$ and $-CO_2CH_2CO_2A$; or a pharmaceutically acceptable salt of said compound with the proviso that

if R^1 is $-CO_2CH_3$ and R^3 is $-H$, then R^2 is not $-CH_2CH_3$, $-CH_2CH_2OH$, or $-CH_2CO_2H$;
if R^1 is $-CO_2CH_3$ and R^3 is $-CO_2CH_2CH_3$, then R^2 is not $-CH_2CH_2$, $-CH_2CH_2OH$, or $-CH_2CO_2H$; and
20 if R^1 is $-CO_2CH_3$ and R^2 is $-CH_2CH_3$, then R^3 is not $-CO_2CH_2CH_2OH$, or $-CO_2CH_2CO_2H$.

25 **2. The compound of claim 1 wherein R^1 is $-CO_2CH_3$, R^3 is $-CO_2CH_2CH_3$, and R^2 is selected from $-CH_2CO_2A$ or $-CH_2CH_2OA$.**


3. The compound of claim 1 wherein R^1 is $-CO_2CH_3$, R^3 is $-H$, and R^2 is selected from $-CH_2CO_2A$ or $-CH_2CH_2OA$.

30 **4. The compound of claim 1 wherein R^1 and R^3 is H, and R^2 is selected from the group consisting of $-CH_2CH_3$, $-CH_2CH_2OH$, $-CH_2CO_2H$, $-CH_2CO_2A$, and CH_2CH_2OA .**

5 5. The compound of claim 1 wherein R¹ is -CO₂CH₃, R² is -CH₂CH₃, and R³ is -CO₂CH₂CO₂A.

6. A compound selected from the group consisting of
 [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-
 10 trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-hydroxyethyl ester;
 [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-
 trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid carboxymethyl ester;
 [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-
 carboxymethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl
 15 ester;
 [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-(2-ethyl-6-trifluoromethyl-1,2,3,4-
 tetrahydro-quinolin-4-yl)-carbamic acid methyl ester;
 [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-[2-(2-hydroxyethyl)-6-
 trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl]-carbamic acid methyl ester; and
 20 [2R, 4S] {4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]- 6-
 trifluoromethyl-1,2,3,4-tetrahydro-quinolin-2-yl}-acetic acid.


7. A compound of Formula II



25 wherein R⁵ is -CH₂CH₃, -CO₂H, -CO₂A, -CH₂CH₂OH,
 -CH₂CO₂H, -CH₂CH₂OA, -CH₂CH₂OSO₃H, -C(O)N(H)CH₂CH₂SO₃H, -
 C(O)N(H)CH₂CO₂H, and -C(O)N(H)C(O)NH₂, and wherein A is 3,4,5-trihydroxy-
 tetrahydropyran-2-carboxylic acid.

30 8. The compound of claim 7 wherein R⁵ is selected from -CH₂CH₃ or
 -CO₂H.

5 9. A compound of Formula III



wherein R⁶ is -CH₂OA, -C(O)N(H)CH₂CO₂A and -CH(SO₃H)N(H)CO₂CH₃, and wherein A is 3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid.

10

10. A method for indicating the presence of or exposure to 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl)-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester in a mammal comprising monitoring the presence of a compound of claim 1 in the mammal.

15

11. A method for indicating the presence of or exposure to 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl)-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester in a mammal comprising monitoring the presence of a compound of claim 6 or 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-hydroxy-ethyl)-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester in the mammal.

20

12. A method for indicating the presence of or exposure to 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl)-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester in a mammal comprising monitoring the presence of a compound selected from the group consisting of a compound of
claim 7, 2-methyl-6-trifluoromethyl-quinoline, and (6-trifluoromethyl-quinolin-2-yl)methanol in the mammal.

30


13. A method for indicating the presence of or exposure to 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl)-6-trifluoromethyl-3,4-

5 dihydro-2H-quinoline-1-carboxylic acid ethyl ester in a mammal comprising monitoring the presence of a compound selected from the group consisting of 3,5-Bis-trifluoromethyl-benzoic acid, 6-(3,5-Bis-trifluoromethyl-benzoyloxy)-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid, 6-(3,5-Bis-trifluoromethyl-benzoyloxy)-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid, (3,5-Bis-

10 trifluoromethyl-phenyl)-methoxycarbonylamino-methanesulfonic acid, (3,5-Bis-trifluoromethyl-benzoylamino)-acetic acid, and (3,5-Bis-trifluoromethyl-benzoylamino)- 3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid in the mammal.

14. A method for indicating the presence of or exposure to 4-[(3,5-bis-15 trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl)-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester in a mammal comprising monitoring the presence of a compound selected from the group consisting of 3,5-bis-trifluoromethylbenzoic acid, 2-methyl-6-trifluoromethyl-quinoline, and 6-trifluoromethyl-quinoline-2-carboxylic acid in the mammal.

20 15. A method for treating atherosclerosis comprising administering to a mammal an atherosclerosis treating amount of a compound of Formula I



wherein

25 R^1 is $-CO_2CH_3$ or $-H$;

R^2 is $-CH_2CH_3$, $-CH_2CH_2OH$, $-CH_2CO_2H$, $-CH_2CO_2A$, and $-CH_2CH_2OA$, wherein A is 3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid; and

R^3 is $-H$, $-CO_2CH_2CH_3$, $-CO_2CH_2CH_2OH$, $-CO_2CH_2CO_2H$, $-CO_2CH_2CH_2OA$ and $-CO_2CH_2CO_2A$; a prodrug thereof, or a pharmaceutically acceptable salt of said compound or of said prodrug with the proviso that

5 if R¹ is -CO₂CH₃ and R³ is -H, then R² is not -CH₂CH₃, -CH₂CH₂OH, or -CH₂CO₂H;
if R¹ is -CO₂CH₃ and R³ is -CO₂CH₂CH₃, then R² is not -CH₂CH₂, -CH₂CH₂OH, or -CH₂CO₂H; and
if R¹ is -CO₂CH₃ and R² is -CH₂CH₃, then R³ is not -CO₂CH₂CH₂OH, or
10 -CO₂CH₂CO₂H, or a compound a compound selected from the group consisting of [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-hydroxyethyl ester; [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid carboxymethyl ester;
15 [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-carboxymethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester; [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-(2-ethyl-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl)-carbamic acid methyl ester;
20 [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-[2-(2-hydroxyethyl)-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl]-carbamic acid methyl ester; [2R, 4S] {4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-2-yl}-acetic acid, and
a prodrug thereof, or a pharmaceutically acceptable amount salt of said compound or
25 of said prodrug.